Search - tctmd.com

Displaying 1 - 20 of 120

Sort: Relevancy | Date

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

News Daily News

Even With Optimized GDMT, HFrEF Prognosis Remains Dire

Michael O'Riordan

January 30, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

News Conference News ESC 2025

NEWTON-CABG CardioLink-5: Evolocumab Doesn’t Prevent SVG Failure

Michael O'Riordan

September 04, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

July 16, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

News Conference News AHA 2024

Indian Patients Do Well on Dual-Combination Pills for Hypertension: TOPSPIN

November 22, 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

July 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

July 01, 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

News Daily News

Most Takotsubo Patients Die From CV Causes, but Standard Meds No Help

January 11, 2024

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

News Daily News

Long-term ALLHAT Data Affirm Parity of Antihypertensive Meds

December 06, 2023

Optimal Care Reported in Less Than Half of Adults With ASCVD

News Daily News

Optimal Care Reported in Less Than Half of Adults With ASCVD

Yael L. Maxwell

December 05, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

October 18, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.